OmniSeq Immune Report Card

OmniSeq has launched its Immune Report Card, an immune profiling test designed to help oncologists select the best mono and combination immunotherapy options for patients. The assay integrates five clinical-grade tests that together provide a comprehensive immune profile. The report card includes CD3/8 and PD-L1 immunohistochemistry, PD-L1/2 copy number using in situ hybridization, microsatellite instability testing, mutational burden analysis via Thermo Fisher Scientific's Ion Torrent next-generation sequencing of 409 exon cancer genes, and cross-validated simultaneous gene expression analysis of 54 critical transcripts via targeted RNA-seq using the Oncomine Immune Response Research Assay. The test is approved by the New York State Clinical Laboratory Evaluation Program, the company said.